CHINA PHARMA HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3216 USD | +3.34% |
|
+1.04% | -46.84% |
| Apr. 01 | China Pharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 23 | China Pharma to Conduct 1-For-5 Reverse Stock Split; Shares Fall After-Hours | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 8.1M | Sales 2023 | 7.01M | Capitalization | 3.99M |
|---|---|---|---|---|---|
| Net income 2022 | -3M | Net income 2023 | -3M | EV / Sales 2022 | 1.44 x |
| Net Debt 2022 | 6.73M | Net Debt 2023 | 3.21M | EV / Sales 2023 | 1.03 x |
| P/E ratio 2022 |
-1.27
x | P/E ratio 2023 |
-0.66
x | Employees | 231 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.37% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.34% | ||
| 1 week | +1.04% | ||
| Current month | +4.72% | ||
| 1 month | -13.10% | ||
| 3 months | -31.86% | ||
| 6 months | -27.97% | ||
| Current year | -46.84% |
1 week
0.30
0.33
1 month
0.270.41
Current year
0.270.64
1 year
0.272.18
3 years
0.2756.00
5 years
0.2781.50
10 years
0.2781.50
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Lin Li
CEO | Chief Executive Officer | 71 | 99-01-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Lin Li
CEO | Chief Executive Officer | 71 | 99-01-27 |
Gene Bennett
BRD | Director/Board Member | 76 | 08-01-31 |
Heung Mei Tsui
BRD | Director/Board Member | 67 | 09-04-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.3216 | +3.34% | 227,146 |
| 24-05-09 | 0.3112 | -1.17% | 117,903 |
| 24-05-08 | 0.3149 | -0.03% | 251,310 |
| 24-05-07 | 0.315 | -1.53% | 165,655 |
| 24-05-06 | 0.3199 | +0.50% | 133,140 |
Delayed Quote Nyse, May 10, 2024 at 04:10 pm EDT
More quotes
China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -46.84% | 4.77M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- CPHI Stock